Profound Medical (TSE:PRN) Trading 0.8% Higher

Shares of Profound Medical Corp. (TSE:PRNGet Rating) traded up 0.8% during trading on Thursday . The company traded as high as C$9.52 and last traded at C$9.37. 16,234 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 51,556 shares. The stock had previously closed at C$9.30.

Separately, Raymond James reiterated a “buy” rating and set a C$23.00 price objective on shares of Profound Medical in a research note on Tuesday, February 22nd.

The company has a quick ratio of 16.50, a current ratio of 18.56 and a debt-to-equity ratio of 1.71. The stock’s 50 day moving average price is C$11.21 and its 200-day moving average price is C$13.21. The stock has a market capitalization of C$194.71 million and a P/E ratio of -4.87.

Profound Medical (TSE:PRNGet Rating) last released its quarterly earnings data on Thursday, March 3rd. The company reported C($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C($0.44) by C($0.18). The firm had revenue of C$1.26 million for the quarter, compared to analysts’ expectations of C$3.52 million. Analysts anticipate that Profound Medical Corp. will post -0.93 earnings per share for the current year.

About Profound Medical (TSE:PRN)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Recommended Stories

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with's FREE daily email newsletter.